Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
ENDPOINTS NEWS7h
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
Business Insider on MSN6d
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
My 10 Top Stocks to Buy to Start the New Year Off Right
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
pharmaphorum1d
Trials set up filing for Lilly’s tirzepatide in sleep apnoea
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...
Lexaria Bioscience price target lowered to $7 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss drugmaker Hims & Hers (HIMS). Read more here.
Morningstar14d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...